Table 1B.
Risks and benefits of pharmacotherapy used for weight loss.
| Composite CV outcomes | CV death | Non-fatal MI | Non-fatal Stroke | SBP | DBP | HR | HDL | LDL | TG | HF | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| STIMULANT MEDICATIONS | |||||||||||
| Phentermine/Topiramate | — | — | — | — |  |
|
 |
|
|
|
— |
| Phentermine | NR | NR | NR | NR | |
|
— | |
|
 |
NR |
| Diethylpropion | NR | NR | NR | NR | |
— | — |  |
|
|
NR |
| Lisdexamfetamine | — | — | — | — | |
— | |
|
|
|
— |
| Lorcaserin | |
|
|
|
|
|
|
|
|
|
|
| Topiramate | — | — | — | — | |
|
— | |
|
|
— |
| Zonisamide | NR | NR | NR | NR | |
|
— | — | — | — | NR |
| Orlistat | NR | NR | NR | NR | |
|
NR | |
— | — | NR |
| Naltrexone/Bupropion* | — | — | — | — | |
— | |
|
|
|
— |
| Bupropion | NR | NR | NR | NR | — | — | |
|
|
|
NR |
Key: Black arrows indicate statistically significant change; gray arrows indicate a non-statistically significant change; NR means not reported; — indicates reported; no change.
*
Study reporting major CV outcomes discontinued due to potential for non-blinding. Abbreviations: CV, cardiovascular; MI, myocardial infarction; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; HDL, high density lipoprotein; LDL, low density lipoprotein; HF, heart failure; TG, triglycerides.